Skip to content

指南针通路

US · CMPS #2952 按市值排名 上市于 2020
10.75 -0.87 -7.49%
实时 - 追踪5344个代码 - 心跳于25秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 18.95 高于历史水平 第95百分位
5年平均 3.67 · 在Medical Care Facilities中排名第39/40
市盈率 -3.05 处于历史正常水平 第63百分位
5年平均 -5.13 · 前瞻 -5.85
市销率 --
5年平均 0.00 · 前瞻 622.54

同业对比 Medical Care Facilities

公司 市值 市盈率(TTM) 市净率 股息率
指南针通路 (CMPS) 1.49B -2.84 17.62 0.00%
HCA Healthcare (HCA) 99.34B 15.39 -14.96 0.65%
Tenet Healthcare (THC) 21.52B 10.33 4.62 0.00%
Encompass Health (EHC) 12.61B 20.83 4.86 0.59%
DaVita (DVA) 11.95B 15.44 -15.62 0.00%
Fresenius Medical Care (FMS) 11.80B 11.90 0.84 3.85%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值8.32 经济护城河None 不确定性Extreme

当前股价高于晨星合理价值估算22.7%。

合理价值

Compass Pathways PLC is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 39% premium over our quantitative fair value estimate of $8.32 per share; however, this estimate should be taken with a pinch of salt due to its extreme uncertainty rating.

The company's valuation metrics undermine our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 5.2%, which falls in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The firm's lack of growth is an additional cause for concern. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's revenue 5-year growth of 0%, for example, ranks in the bottom 20% compared with global peers. Weak trailing five-year revenue growth is disappointing and could indicate trouble generating future value for shareholders, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

指南针通路 讨论区 0 条评论

发表评论